MAXIO combines tumour visualisation in 3D and procedure planning with robotic targeting that helps clinicians achieve consistent procedure quality. During the planning phase, clinicians can ‘see’ the tumour and surrounding structures, determine the best approach to reach the tumour, select the appropriate number and type of energy probes, visualize estimated ablation volumes and determine the sequence of probe placement. MAXIO’s robotic targeting system then helps the clinician advance the probes as planned, to reach the tumour safely. Once the ablation procedure has been performed, MAXIO’s visualisation tools help clinicians to verify and extend the procedure if needed. The tool helps simplify complex procedures while ensuring a high degree of accuracy.
Commenting on his company’s latest innovation, Nandakumar Subburaman, CEO and Founder of Perfint Healthcare stated, “Interventional Oncology and in specific tumour ablation is rapidly becoming an effective alternate to surgical treatment for cancer, globally. MAXIO brings the practice of interventional oncology to a whole new level.” He added, “Our goal was to create a solution that would make life-saving ablation procedures available to a greater number of cancer sufferers. To do that, we realised that the complex techniques used by interventional radiologists would have to be made simpler and more predictable. That’s what we’ve done with MAXIO”.
Tumour ablation is an effective alternate to surgery for inoperable tumours. Tumour ablation is an image guided minimally invasive procedure in which devices such as needles are used to deliver thermal or other energy to destroy the tumour. Visualisation, planning and needle placement are key to successful tumour ablation. MAXIO helps clinicians visualize, plan and perform tumour ablation safely with consistent quality
MAXIO was developed through support under the BIPP scheme of the Department of Biotechnology and meets the best-in-class standards globally. The product complies with CE marking requirements.
MAXIO’s workflow and robotic targeting will make it easy for large scale adoption of tumour ablation in highly populous societies such as in India, China, Indonesia and Latin America – where there is an urgent need to create high quality cancer care infrastructure, quickly and at a low cost.